戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 dent (NIH 3T3 and NRK) cells to an HTLV-1 SU immunoadhesin.
2 nst RCANBP virions and SU-A-immunoglobulin G immunoadhesin.
3 oduced between the D1 and Fc portions of the immunoadhesin.
4  studies were performed with a subgroup A SU-immunoadhesin.
5 ally reduced the binding affinity for the SU-immunoadhesin.
6 eductions in the binding affinity for the SU-immunoadhesin.
7 tant structural and functional principles of immunoadhesins.
8                  Recent studies suggest that immunoadhesins also may be useful therapeutically, as in
9 ding of the HTLV-1 surface glycoprotein (SU) immunoadhesin and transduction by HTLV-1 pseudotyped vir
10 n scheme avoids the shortcomings of previous immunoadhesins and can be used to combat other zoonotic
11 olyethylene glycol-conjugated Fab molecules, immunoadhesins, and albumin fusions, suggesting a novel
12 tion, we highlight some unique advantages of immunoadhesins as experimental tools in biology, as well
13 ivalent PECAM-1 in the form of a PECAM-1/IgG immunoadhesin, associated homophilically with cells expr
14                                        These immunoadhesins bind beta-glucan with high affinity, and
15                                       The SU-immunoadhesin bound the wild-type Tva protein with a KD
16                                 Furthermore, immunoadhesins can be used not only to impair but also t
17 CD4 domains of the HIV-1-entry inhibitor CD4 immunoadhesin (CD4-Ig).
18 f BDNF is critical to this effect we used an immunoadhesin chimera (TrkB-IgG) that inactivates free B
19                           We used a specific immunoadhesin chimera (TrkB-IgG) that mimics the BDNF re
20 investigated the neutralization potencies of immunoadhesins compared to those of their parent IgGs.
21  between the TEF CAR1-related protein and an immunoadhesin composed of the surface (SU) envelope prot
22 ne-stimulating properties, we have developed immunoadhesins consisting of the carbohydrate binding do
23          Blockade of FasL with a soluble Fas immunoadhesin does not prevent liver injury in animals t
24                                           An immunoadhesin form of one of these, CCR5mim2-Ig, synergi
25 ed to those of the parent IgG, and the VRC01 immunoadhesin formed dimers and multimers with reduced n
26 ciently than CD4-Fc or equimolar mixtures of immunoadhesin forms of each peptide.
27 eraction of HAV with havcr-1, we constructed immunoadhesins fusing the hinge and Fc portion of human
28 geting, which is based on the application of immunoadhesins, genetically engineered fusion proteins t
29 ector expressing antibodies or antibody-like immunoadhesins having predetermined SIV specificity.
30 acting partners; for example, use of a novel immunoadhesin HN125 to interfere MUC16 binding to mesoth
31 enerated an HTLV-I surface glycoprotein (SU) immunoadhesin, HTSU-IgG, which binds specifically to cel
32 y near-quantitative formation of an antibody/immunoadhesin hybrid in a cotransfection assay.
33                      Such proteins, known as immunoadhesins (IA), were highly expressed following tra
34                                           An immunoadhesin is a fusion protein that combines the targ
35                               The prototypic immunoadhesin is an antibody-like molecule that fuses th
36 rahippocampal infusion of an EphA antagonist immunoadhesin leads to impaired performance in two behav
37                                        These immunoadhesins modulate the activity of not only a singl
38 glycosylation experiments using TNFR-IgG, an immunoadhesin molecule, as a model therapeutic glycoprot
39 CCR5- and CD4-mimetic peptides, expressed as immunoadhesins, neutralize HIV-1 more efficiently than C
40 extracellular domains of LFA-1 and a dimeric immunoadhesin of ICAM-1.
41                                              Immunoadhesins provide a unique tool for identifying unk
42 ess, since pretreatment with the soluble Fas immunoadhesin reduces liver injury in this model.
43 activation of EphA by infusion of an agonist immunoadhesin results in enhanced performance on these t
44 For the antibodies VRC01, PG9, and PG16, the immunoadhesins showed modestly reduced potencies, likely
45                                              Immunoadhesin (single-chain fragment variable [scFv]-Fc)
46                                          The immunoadhesin specifically bound to adult T cells, B cel
47                        Initial studies using immunoadhesins suggest that protein targeting might be a
48  for EphA receptors, we designed recombinant immunoadhesins that specifically bind to the receptor bi
49 a novel tumor necrosis factor-alpha receptor immunoadhesin, the increased mortality was completely pr
50      Thirty-five point mutants of the ICAM-1 immunoadhesin were generated and residues important for
51                                        These immunoadhesins were secreted to the cell culture medium
52                           The recombinant SU-immunoadhesins were used as probes to investigate the ce
53 dentified in a screen for binding to MuSK-Fc immunoadhesin, were examined for ability to induce proli